{"id":2899,"date":"2026-08-25T13:27:45","date_gmt":"2026-08-25T12:27:45","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/fr\/?post_type=product&p=2899"},"modified":"2026-08-25T13:27:45","modified_gmt":"2026-08-25T12:27:45","slug":"buy-n-acetyl-selank-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/fr\/product\/buy-n-acetyl-selank-in-switzerland\/","title":{"rendered":"N-Acetyl Selank (10MG)"},"content":{"rendered":"

What Is N-Acetyl Selank and Why Buy It for Research?<\/strong><\/h2>\n

Buy N-Acetyl Selank in Switzerland for research into neuropeptide signaling, GABAergic modulation, and cognitive enhancement pathways. Specifically, N-Acetyl Selank (also known as Ac-Selank, Acetyl Selank, or N-Acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic acetylated heptapeptide with the sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH (one-letter code: Ac-TKPRPGP). It is the N-terminally acetylated derivative of Selank, a heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.<\/p>\n

Selank itself is a stabilized analogue of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), a fragment of the immunoglobulin G heavy chain. Selank gained approval in Russia in 2009 as an intranasal anxiolytic for treating generalized anxiety disorder and neurasthenia. The N-acetyl modification involves covalent attachment of an acetyl group (CH3CO-) to the free alpha-amino group of the N-terminal threonine residue. The peptide has a molecular weight of approximately 793.9 Da and the molecular formula C\u2083\u2083H\u2085\u2087N\u2081\u2081O\u2089. The CAS number for the parent compound Selank is 129954-34-3.<\/p>\n

In scientific research, N-Acetyl Selank serves as a molecular tool for studying neuropeptide signaling pathways, GABAergic modulation, and neuroimmune regulation. Furthermore, Core Peptides supplies N-Acetyl Selank as a lyophilized powder in a 10mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available when they buy N-Acetyl Selank in Switzerland.<\/p>\n

N-Acetyl Selank Research Overview: Buy N-Acetyl Selank in Switzerland for Neuropeptide Studies<\/strong><\/h2>\n

Centrally, research into N-Acetyl Selank has focused on its function as a stabilized analogue of Selank with enhanced resistance to enzymatic degradation. The acetylation protects the peptide from aminopeptidase-mediated cleavage, thereby extending its half-life and potentially improving bioavailability. Unmodified Selank has an exceptionally short plasma half-life of approximately 2-3 minutes, which necessitates frequent dosing for CNS delivery. Consequently, researchers designed the acetylated derivative to extend this half-life by reducing the rate of N-terminal enzymatic cleavage, potentially allowing lower doses and less frequent administration to achieve equivalent pharmacological effects.<\/p>\n

N-Acetyl Selank mirrors the pharmacological profile of Selank, as acetylation does not alter the peptide’s receptor-binding pharmacophore. The pharmacological profile of Selank encompasses three primary domains: anxiolytic, nootropic, and immunomodulatory activity. The anxiolytic effects arise through allosteric modulation of GABA-A receptors, enhanced brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex, and modulation of serotonergic neurotransmission. Notably, unlike benzodiazepines, Selank and its N-acetyl derivative produce anxiolysis without sedation, cognitive impairment, tolerance development, or physical dependence.<\/p>\n

The nootropic effects include enhanced memory consolidation, improved attention, and facilitated learning. Researchers attribute these effects to BDNF-mediated neuroplasticity, cholinergic modulation, and stabilization of enkephalin metabolism in the brain. The immunomodulatory dimension, inherited from its tuftsin core, involves stimulation of IL-6 expression, modulation of T-helper cell balance (Th1\/Th2), and enhancement of monocyte\/macrophage activity. Accordingly, researchers who buy N-Acetyl Selank in Switzerland from Core Peptides can support their investigations into neuropeptide signaling, GABAergic modulation, and neuroimmune regulation.<\/p>\n

How Does N-Acetyl Selank Work in Research?<\/strong><\/h2>\n

Mechanistically, N-Acetyl Selank’s proposed action involves functioning as a multi-target neuroactive peptide that modulates GABAergic, serotonergic, and neurotrophic pathways. The peptide operates through several interconnected mechanisms.<\/p>\n

GABAergic Modulation<\/strong><\/h3>\n

N-Acetyl Selank modulates the GABAergic system through allosteric modulation of GABA-A receptors. Research suggests that Selank may alter the binding properties of GABA to its receptors, perhaps via allosteric modulation, thereby influencing inhibitory neurotransmission. In neuronal preparations, Selank has been associated with a shift in specific GABA binding without necessarily altering affinity, indicating modulation of receptor state rather than direct agonism. By analogy, N-Acetyl Selank appears to retain or even tune such modulatory potential. Furthermore, unlike benzodiazepines, Selank and its N-acetyl derivative produce anxiolysis without sedation, cognitive impairment, or tolerance development.<\/p>\n

BDNF Upregulation and Neuroplasticity<\/strong><\/h3>\n

Studies associate N-Acetyl Selank with the rapid upregulation of brain-derived neurotrophic factor (BDNF) in hippocampal tissue in research models. This BDNF-mediated neuroplasticity contributes to the peptide’s nootropic effects, including enhanced memory consolidation, improved attention, and facilitated learning.<\/p>\n

Serotonergic Neurotransmission<\/strong><\/h3>\n

Research implicates Selank in modulating monoamine neurotransmitter concentrations, including serotonin metabolism and turnover. Evidence suggests that Selank may upregulate serotonin metabolism or availability in brain regions. Consequently, N-Acetyl Selank might influence serotonergic signaling more persistently or with different temporal profiles.<\/p>\n

Enkephalinase Inhibition and Endogenous Peptide Regulation<\/strong><\/h3>\n

Selank inhibits peptide-degrading enzymes (such as enkephalinases), thereby elevating endogenous regulatory peptides like enkephalins. If N-Acetyl Selank preserves or enhances such inhibitory capacity, it could serve as a modulator of endogenous peptide signaling systems. In research contexts focused on neuropeptide regulation, enkephalin turnover, or peptidase assays, N-Acetyl Selank may act as a chemical tool to transiently suppress peptidase activity.<\/p>\n

Immunomodulatory Activity<\/strong><\/h3>\n

The immunomodulatory dimension of N-Acetyl Selank, inherited from its tuftsin core, involves stimulation of IL-6 expression, modulation of T-helper cell balance (Th1\/Th2), and enhancement of monocyte\/macrophage activity. This positions N-Acetyl Selank as a uniquely multi-target compound that bridges the neuroimmune axis\u2014addressing both the psychological and immunological components of stress-related disorders.<\/p>\n

Why Is N-Acetyl Selank Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study N-Acetyl Selank because it represents a well-characterized acetylated heptapeptide that enables investigation of neuropeptide signaling, GABAergic modulation, and neuroimmune regulation. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying anxiety, cognitive function, and stress-related disorders.<\/p>\n

Research has demonstrated N-Acetyl Selank’s relevance across multiple domains. For example, researchers have studied the peptide for its potential to modulate GABA-A receptor sensitivity, promoting inhibitory neurotransmission and anxiolytic effects. Selank has been shown to improve cognitive and emotional state in patients with generalized anxiety disorder. Furthermore, studies demonstrate that Selank attenuates aversive signs of morphine withdrawal and protects against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex.<\/p>\n

Moreover, investigators have examined N-Acetyl Selank for its neuroprotective potential and its ability to modulate the expression of genes involved in inflammation. The peptide also exerts antiulcerogenic action and promotes healing of experimental ulcers. Ultimately, researchers who buy N-Acetyl Selank in Switzerland gain access to a comprehensive research tool for investigating neuropeptide signaling, GABAergic modulation, and neuroimmune regulation.<\/p>\n

N-Acetyl Selank Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nEvidence Level<\/th>\n<\/tr>\n<\/thead>\n
GABAergic Modulation<\/td>\nGABA-A receptor allosteric modulation, inhibitory neurotransmission, anxiolytic mechanisms<\/td>\nMechanistic \/ Preclinical<\/td>\n<\/tr>\n
BDNF and Neuroplasticity<\/td>\nBDNF upregulation, synaptic plasticity, memory consolidation, learning enhancement<\/td>\nPreclinical<\/td>\n<\/tr>\n
Serotonergic Neurotransmission<\/td>\nSerotonin metabolism, monoamine modulation, receptor sensitivity<\/td>\nMechanistic \/ Preclinical<\/td>\n<\/tr>\n
Neuropeptide Signaling<\/td>\nEnkephalinase inhibition, endogenous peptide regulation, peptidase assays<\/td>\nMechanistic \/ In Vitro<\/td>\n<\/tr>\n
Immunomodulation<\/td>\nIL-6 expression, T-helper cell balance, monocyte\/macrophage activity<\/td>\nMechanistic \/ Preclinical<\/td>\n<\/tr>\n
Cognitive Research<\/td>\nMemory consolidation, attention, learning, neuroprotection<\/td>\nPreclinical \/ Clinical<\/td>\n<\/tr>\n
Stress and Anxiety Research<\/td>\nAnxiolytic effects, stress response, behavioral regulation<\/td>\nPreclinical \/ Clinical<\/td>\n<\/tr>\n
Peptide Stability Studies<\/td>\nAminopeptidase resistance, metabolic stability, enzymatic degradation assays<\/td>\nMechanistic \/ In Vitro<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

N-Acetyl Selank Compared With Related Research Compounds<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Compound<\/th>\nResearch Focus<\/th>\nMechanism \/ Target<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
N-Acetyl Selank<\/td>\nAnxiolytic, nootropic, immunomodulatory<\/td>\nGABA-A allosteric modulation, BDNF upregulation, enkephalinase inhibition<\/td>\nAcetylated heptapeptide; enhanced stability; multi-target profile<\/td>\n<\/tr>\n
Selank<\/td>\nAnxiolytic, nootropic, immunomodulatory<\/td>\nGABA-A allosteric modulation, BDNF upregulation<\/td>\nParent heptapeptide; shorter half-life (~2-3 min); Russian-approved drug<\/td>\n<\/tr>\n
N-Acetyl Semax<\/td>\nNootropic, neuroprotective, cognitive enhancement<\/td>\nBDNF upregulation, dopaminergic modulation<\/td>\nDifferent peptide sequence; stimulatory profile; complementary mechanism<\/td>\n<\/tr>\n
Tuftsin<\/td>\nImmunomodulatory<\/td>\nMacrophage activation, immune regulation<\/td>\nNative tetrapeptide; parent compound; shorter half-life<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, N-Acetyl Selank differs from its parent compound Selank in its enhanced stability and potentially improved bioavailability. On the one hand, Selank is the parent heptapeptide approved in Russia as an anxiolytic, with a short half-life of approximately 2-3 minutes. On the other hand, N-Acetyl Selank features N-terminal acetylation that protects the peptide from aminopeptidase degradation, extending its half-life and potentially allowing lower doses.<\/p>\n

Research Applications for N-Acetyl Selank in Switzerland<\/strong><\/h2>\n

Scientists have investigated N-Acetyl Selank across several research domains:<\/p>\n